Coronavirus disease (COVID-19) science conversation
In this video and audio series WHO experts explain the science related to COVID-19. This series is available every week on WHO's YouTube, Instagram, Facebook, Twitter, and LinkedIn channels and on all major podcasts platforms.
Download all epis...ode transcripts in Arabic, Chinese, English, French, Portuguese, Russian, Spanish, Hindi, Maithili, Nepali
more
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also interacting with medicine developers and making use of real-world data to monitor the safety and effectiveness of medicines use...d in patients with COVID-19.
more
Ausführliche Informationen zu klinischen Prüfungen und Risiken für bestimmte Gruppen sowie zu Wechselwirkungen und Nebenwirkungen von Impfstoffen und Arzneimitteln zu COVID-19 und SARS-CoV-2
Mobile vaccination teams visiting long-term care homes will have an important role in providing vaccination coverage for some of the most vulnerable population sub-groups. However, based on the experiences of German mobile diagnostic teams during the first COVID-19 pandemic w...ave, the deployment of mobile vaccination teams to care homes for older adults and people with disabilities is expected to raise various ethical challenges.
more
This guide provides valuable resources for both, Healthcare Professionals (physicians, nurses and practitioners) and Health Consumers about the COVID-19 outbreak and recent research related to this topic.
The overall goal of this strategy is to ensure accurate understanding of the
benefits of covid-19 vaccination and alleviate apprehension about the vaccine, to ensure its acceptance and encourage uptake across various audiences.
Objectives
x Create demand, promote acceptability and accessibility o...f COVID-19
vaccine among at least 90% of the general public.
x Develop appropriate messages and identify channels to communicate
the potential benefits and risks of the vaccine to all concerned parties,
including decision-makers at all levels.
x Provide timely and accurate information to address misinformation,
rumors and other crisis situations.
x Effectively mobilize and empower communities to ensure participation
and ownership of the vaccination process
x Strengthen communication mechanisms and partnerships among key
stakeholders to support the national communication effort.
more
Entwicklungen und gegenwärtige Situationen der Covid-19-Impfstoffe
26 July 2021
Hesperian created a 4-language Glossary of Health Terms for health workers cooperating across language barriers. These resources will be of use during this crisis by both Haitian health workers and any foreign health workers working in solidarity with them.
A Organização Mundial da Saúde (OMS), com apoio do Grupo Consultivo Estratégico de Especialistas em Imunização (Strategic Advisory Group of Experts on Immunization – SAGE) e do respectivo Grupo de Trabalho para Vacinas contra a COVID-19, está analisando novas evidências sobre o uso de vaci...nação heteróloga (conhecida também como vacinação mix and match). Na vacinação heteróloga, a segunda dose usa uma vacina diferente da que foi usada na primeira dose. Reforço heterólogo, por outro lado, refere-se à administração de uma vacina com plataforma tecnológica diferente da que foi usada para concluir o esquema primário de vacinação. Esta declaração provisória diz respeito apenas à vacinação heteróloga, e não ao reforço heterólogo.
more
Достоверные ответы и конкретная информация о том, как защитить себя и помочь другим.
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p...andemic and the challenge of implementing a large-scale vaccine rollout—and in the coming years—as new variants develop and unceertainty about the vaccination strategy increases.
more
Establecida en 1902 como el organismo independiente especializado en salud del sistema interamericano, la Organización Panamericana de la Salud (OPS) ha desarrollado competencias y experiencia ampliamente reconocidas al brindar cooperación técnica a sus Estados Miembros para combatir las enfermed...ades transmisibles y no transmisibles y sus causas, fortalecer los sistemas de salud y responder a situaciones de emergencia y desastres en toda la Región de las Américas. Asimismo, en su calidad de oficina regional de la Organización Mundial de la Salud, la OPS participa activamente en los equipos de las Naciones Unidas en los países, colaborando con otros organismos, fondos y programas del sistema de las Naciones Unidas para contribuir al logro de los Objetivos de Desarrollo Sostenible (ODS) a nivel de país.
more
El presente protocolo de vacunación contra la COVID-19 para personas que padecen diabetes mellitus tipo 2 es de aplicación en las Instituciones Prestadoras de Servicios de Salud del Ministerio de Salud, a través de las Direcciones de Redes Integradas de Servicios de Salud y de los Gobiernos Regio...nales, a través de las Direcciones Regionales de Salud o Gerencias Regionales de Salud, EsSalud, Sanidad de las fuerzas armadas y policiales y las entidades privadas.
En el documento encontrarás información referida al flujo de atención (admisión, triaje, punto de vacunación, monitoreo y observación), consideraciones generales y específicas, entre otros.
Esta publicación pertenece al compendio Protocolos de vacunación contra la COVID-19
more
Lymphatic filariasis (LF), a neglected tropical disease, is targeted for global elimination as a public health problem. This article reviews the history of LF control and elimination activities in the countries of the World Health Organization's (WHO) Eastern Mediterranean Region (EMR) over the last... 2 decades. In 2000, the estimated at-risk population in EMR countries was 12.6 million people, accounting for approximately 1% of the global disease burden. Of the 22 EMR countries, 3 countries (Egypt, Sudan and Yemen) were LF endemic and the disease was suspected in 4 other countries (Djibouti, Oman, Somalia and Saudi Arabia). After almost 2 decades of implementing sustained control and prevention measures, Egypt and Yemen were successfully validated by the WHO as having achieved the elimination criteria in 2017 and 2019, respectively. In 2018, Sudan completed mapping of LF, reaching 26.2% geographical coverage where mass drug administration (MDA) is required and is scaling-up MDA. Extensive epidemiological assessment indicated the absence of LF transmission in the four suspected countries and no MDA required. Challenges faced during the elimination and post-elimination phases are described and discussed
more